Technologies to Deliver Next Generation Cancer Therapies

Juno is exploring the potential of our CAR and TCR technologies to treat cancers not currently targeted by our CD19-directed product candidates – in particular, an additional target for B cell malignancies and targets for difficult-to-treat solid organ tumors such as certain breast, lung, ovarian and pancreatic cancers. We and our collaborators are working on a number of product candidates in early clinical development that target different cancer proteins. Molecules of interest that are targets of early stage CAR and TCR clinical exploration are CD22, WT-1, L1CAM (CD171), MUC16/IL-12, and ROR1.